RN7SL36P

Across TCGA pan-cancer cohorts, RN7SL36P RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated RN7SL36P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RN7SL36P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RN7SL36P expression acts as an unfavorable survival marker, although some lineages such as MESO and ESCA show a favorable association.

LIHC, MESO, and THCA are the cancer types where RN7SL36P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	II,III,IV	0.132	0.434	.001	78	view →
MESO	DFS	Tertile	III,IV	0.856	0.246	.006	51	view →
THCA	OS	Tertile	IV	0.579	1.000	<.001	45	view →
LGG	OS	Tertile	All	0.690	0.835	<.001	42	view →
LUAD	DFS	Tertile	IV	0.107	0.667	<.001	36	view →
PCPG	DFS	Tertile	All	0.442	0.868	<.001	21	view →
UVM	OS	Tertile	All	0.292	0.674	.035	18	view →
UCEC	OS	Tertile	All	0.865	0.932	.013	18	view →
ESCA	DFS	Tertile	III,IV	0.459	0.233	.010	17	view →
STAD	DFS	Quartile	III,IV	0.374	0.565	.019	12	view →
COAD	OS	Tertile	II,III,IV	0.558	0.802	.020	12	view →
GBM	OS	Tertile	All	0.703	0.361	.017	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

RN7SL36P–LIHC (DFS)

Open the LIHC breakdown →